JAK Inhibitor Safety Study Seen Altering Practice in the VA

(MedPage Today) -- Safety risks found in a postmarketing trial with the Janus-associated kinase (JAK) inhibitor tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for rheumatoid arthritis (RA) patients in the...
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news